Flotek Industries Inc: Form 10-K/A for the period ended Dec 31, 2019
Filed with the SEC on Jun 11, 2020 and accepted by EDGAR at Jun 10, 2020, 21:08 ET.
Controls and procedures
As filed, 5,968 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Restated Evaluation of Disclosure Controls and Procedures
The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in reports filed or submitted under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. The Company’s disclosure controls and procedures are also designed to ensure such information is accumulated and communicated to management, including the principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosures. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance that control objectives are attained. The Company’s disclosure controls and procedures are designed to provide such reasonable assurance.
Subsequent to the filing of its Annual Report on 10-K for the fiscal year ended December 31, 2019, the Company identified two deficiencies in its internal control over financial reporting. Specifically, the Company’s management determined that the Company did not, as of December 31, 2019, design and maintain effective internal controls over the elimination of intercompany profits in inventory reported between September 1, 2018 and December 31, 2019, or the recording of legal rights to certain intangible assets related to the sale of Florida Chemical Company on February 28, 2019.
The Company does not believe that the control deficiencies resulted in a material misstatement of the Company’s consolidated financial statements included in this Annual Report on Form 10-K for the fiscal year ended December 31, 2019. The Company subsequently adjusted prior periods in 2019 to reflect appropriate revisions, as previously disclosed in the Company’s press release dated May 18, 2020, and its Current Report on Form 8-K furnished on May 19, 2020.
After further review, the Company has determined that the control deficiencies constitute material weaknesses in its internal control over financial reporting as of December 31, 2019. In addition, the Company’s management, including its principal executive officer and principal financial officer, have evaluated the effectiveness of the Company’s disclosure controls and procedures, as required by Rule 13a-15(e) of the Exchange Act as of December 31, 2019 and has concluded that the Company’s disclosure controls and procedures were not effective as of December 31, 2019 due to the material weaknesses in internal control over financial reporting described above.
The Company believes that, notwithstanding the material weaknesses mentioned above, the consolidated financial statements contained in this Form 10-K present fairly, in all material respects, the consolidated financial positions, results of operations and cash flows of the Company and its subsidiaries in conformity with generally accepted accounting principles in the United States as of the dates and for the periods stated therein.
Restated Management’s Report on Internal Control over Financial Reporting
The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) of the Exchange Act. The Company’s management, including the principal executive and principal financial officers, assessed the effectiveness of internal control over financial reporting as of December 31, 2019, based on criteria issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) (“COSO”) in Internal Control – Integrated Framework. Upon evaluation, the Company’s management has concluded that the Company’s internal control over financial reporting was not effective in connection with the preparation of the consolidated financial statements as of December 31, 2019.
Subsequent to the filing of its Annual Report on 10-K for the fiscal year ended December 31, 2019, the Company identified two deficiencies in its internal control over financial reporting. Specifically, the Company’s management determined that the Company did not, as of December 31, 2019, design and maintain effective internal controls over the elimination of intercompany profits in inventory reported between September 1, 2018 and December 31, 2019, or the recording of legal rights to certain intangible assets related to the sale of Florida Chemical Company on February 28, 2019.
The effectiveness of the Company’s internal control over financial reporting as of December 31, 2019 has been audited by Moss Adams LLP, an independent registered public accounting firm, as stated in their report which is included herein.
Restated Changes in Internal Control over Financial Reporting
Subsequent to the filing of its Annual Report on 10-K for the fiscal year ended December 31, 2019, the Company identified two control deficiencies that constitute material weaknesses related to the elimination of intercompany profits in inventory and recording legal rights to certain intangible assets described above. The Company believes that it has taken appropriate action in its design and implementation of internal controls to remediate the two control deficiencies described above. In addition, the Company will continue to evaluate its internal controls and monitor the effectiveness of the actions taken to remediate the control deficiencies.
There have been no changes in the Company’s system of internal control over financial reporting during the three months ended December 31, 2019 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-10-01 to 2019-12-31 | $19.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2019-01-01 to 2019-12-31 | $119.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months2019-01-01 to 2019-12-31 | $8.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2019-01-01 to 2019-12-31 | $28.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-10-01 to 2019-12-31 | −$36.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2019-01-01 to 2019-12-31 | −$76.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2019-01-01 to 2019-12-31 | $2.0m | us-gaap:InterestExpense |
| Income tax | 12 months2019-01-01 to 2019-12-31 | −$201.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-10-01 to 2019-12-31 | −$39.6m | us-gaap:NetIncomeLoss |
| Net income | 12 months2019-01-01 to 2019-12-31 | −$32.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-10-01 to 2019-12-31 | −$0.68 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2019-01-01 to 2019-12-31 | −$0.55 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-10-01 to 2019-12-31 | −$0.68 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2019-01-01 to 2019-12-31 | −$0.55 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2019-01-01 to 2019-12-31 | 58,750,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | $2.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2019-01-01 to 2019-12-31 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2019-12-31 | $100.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-12-31 | $152.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-12-31 | $231.8m | us-gaap:Assets |
| Current liabilities | At period end2019-12-31 | $41.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-12-31 | $58.6m | us-gaap:Liabilities |
| Current portion of debt | At period end2019-12-31 | $0 | us-gaap:LongTermDebtCurrent |
Source: SEC EDGAR, the filing index for accession 0000928054-20-000105. Last ingested by Listed: Nov 14, 2026, 17:51 ET. Listed shows no prices and gives no investment advice.